Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Gilead Sciences : Australia's Victoria state logs another day of high coronavirus infections

share with twitter share with LinkedIn share with facebook
07/10/2020 | 10:42pm EDT

(Adds comments from deputy chief medical officer, national total)

SYDNEY, July 11 (Reuters) - Australia's second most-populous state reported one of its highest daily increases in coronavirus infections on Saturday and warned the numbers would get worse before they got better as its capital city began its first weekend of a six-week lockdown.

The state of Victoria logged 216 new cases, down from a record 288 the previous day but still one of the biggest daily increases of any part of the country.

"We will see more and more additional cases. This is going to be with us for months and months," Victorian Premier Daniel Andrews told a televised news conference.

"Nobody is enjoying being locked at home. It is frustrating, it is challenging, but the strategy will be successful if we all play our part."

Victoria, home to a quarter of the country's 25 million people, has also become the first state to ask people to wear masks with the order directed at residents of Melbourne.

The other seven states and territories, which reported just 11 new cases between them on Saturday, have banned travellers from Victoria amid concern that community transmission was causing a second wave of the virus. Authorities had previously attributed most new cases to people returning from overseas.

The country's deputy chief medical officer, Nick Coatsworth, said it was to soon to say whether the community transmission had spread from Victoria to other states.

"We are all on high alert," he said. "It is fair to say that the next couple of days are critical."

Australia has avoided the high COVID-19 casualty numbers of other countries after closing its borders and going into nationwide lockdown in March, with some 9,300 infections and 107 deaths.

There were seven new cases in neighbouring New South Wales, the most-populous state, including a man who had visited a Sydney pub that has been linked to two other infections, authorities said. A pop-up testing clinic was set up at the pub so patrons who were there on the same night could be tested.

Australia on Friday gave provisional approval to Gilead Sciences Inc's remdesivir as the first treatment option for virus, joining the United States and the European Commission.

(Reporting by Byron Kaye; Editing by William Mallard and Edwina Gibbs)

share with twitter share with LinkedIn share with facebook
Latest news on GILEAD SCIENCES, INC.
12:13pGILEAD SCIENCES : State attorneys general urge U.S. to increase supply, lower pr..
RE
11:45aGILEAD SCIENCES : State attorneys general urge U.S. govt to increase supply, low..
RE
03:58aSun Pharma latest to sell COVID-19 drug favipiravir in India
RE
08/03Gilead Shows the Dangers of Covid-19 Drug Mania -- Heard on the Street
DJ
08/03Rival drugmakers launch joint trial of medicines for COVID-19
RE
07/31EXCLUSIVE : China-backed hackers 'targeted COVID-19 vaccine firm Moderna'
RE
07/31Merck to move COVID-19 treatment into large trials, sees sales recovering thi..
RE
07/31GLOBAL MARKETS LIVE: A flurry of earnings reports, day 3
07/31EXCLUSIVE : China-backed hackers 'targeted COVID-19 vaccine firm Moderna'
RE
07/31China-backed hackers 'targeted COVID-19 vaccine firm Moderna'
RE
More news
Financials (USD)
Sales 2020 24 071 M - -
Net income 2020 2 800 M - -
Net Debt 2020 11,3 M - -
P/E ratio 2020 39,5x
Yield 2020 3,77%
Capitalization 89 976 M 89 976 M -
EV / Sales 2020 3,74x
EV / Sales 2021 3,65x
Nbr of Employees 11 800
Free-Float 99,4%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 80,16 $
Last Close Price 71,73 $
Spread / Highest target 35,2%
Spread / Average Target 11,8%
Spread / Lowest Target -13,6%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.10.39%87 217
VERTEX PHARMACEUTICALS27.66%70 523
REGENERON PHARMACEUTICALS71.83%64 189
WUXI APPTEC CO., LTD.73.65%37 214
GENMAB A/S52.01%23 205
BIONTECH SE152.27%19 556